<DOC>
<DOCNO>EP-0648767</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Piperdine and piperazine derivatives which affect the C.N.S.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2500	A61K31452	A61P2524	A61K31495	A61P2520	A61P4300	A61P2500	A61P900	A61P2526	C07D40512	A61P2504	A61P902	A61K314965	A61K31445	A61K31452	A61K314427	A61P2518	A61K31495	A61K314965	A61K31445	A61P4300	C07D40514	A61K31443	C07D40500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	A61P	A61K	A61P	A61P	A61P	A61P	A61P	C07D	A61P	A61P	A61K	A61K	A61K	A61K	A61P	A61K	A61K	A61K	A61P	C07D	A61K	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P25	A61K31	A61P25	A61K31	A61P25	A61P43	A61P25	A61P9	A61P25	C07D405	A61P25	A61P9	A61K31	A61K31	A61K31	A61K31	A61P25	A61K31	A61K31	A61K31	A61P43	C07D405	A61K31	C07D405	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Piperidine and piperazine derivatives of the formula I 
<
IMAGE
>
  wherein   Ind is an unsubstituted indol-3-yl radical or one which is mono- or disubstituted by OH, OA, CN, Hal, COR
<
2
>
 or CH2R
<
2
>
, R' is benzofuran-5-yl or 2,3-dihydrobenzofuran-5-yl, chroman-6-yl, chroman-4-on-6-yl, 3-chromen-6-yl or chromen-4-on-6-yl which are unsubstituted or monosubstituted by CN, CH2OH, CH2OA or COR
<
2
>
,   Q is CmH2m,   Z is N or CR
<
3
>
,   A is alkyl having 1-6 C atoms,   Hal is F, Cl, Br or I,   R
<
2
>
 is OH, OA, NH2, NHA or NA2,   R
<
3
>
 is H, OH or OA and   m is 2, 3 or 4, and their physiologically acceptable salts affect the central nervous system.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Piperidine and piperazine derivatives of the 
formula I 


 
wherein 


Ind
is an indol-3-yl radical which is unsubstituted or 
mono- or polysubstituted by OH, OA, CN, Hal, COR
2
 or 
CH
2
R
2
R
1
is benzofuran-5-yl or 2,3-dihydrobenzofuran-5-yl, 
chroman-6-yl, chroman-4-on-6-yl, 3-chromen-6-yl or 

chromen-4-on-6-yl, which is unsubstituted or mono-substituted 
by CN, CH
2
OH, CH
2
OA or COR
2
, 
Q
is C
m
H
2m
, 
Z
is N or CR
3
, 
A
is alkyl having 1-6 C atoms, 
Hal
is F, Cl, Br or I, 
R
2
is OH, OA, NH
2
, NHA or NA
2
, 
R
3
is H, OH or OA and 
m
is 2, 3 or 4, 
 
and their physiologically acceptable salts. 
(a) 1-[4-(5-Methoxyindol-3-yl)butyl]-4-(2-hydroxymethylbenzofuran-5-yl)piperazine; 
(b) 1-[4-(5-carbamoylindol-3-yl)butyl]-4-hydroxy-4-(2,3-dihydrobenzofuran-5-yl)piperidine; 
(c) 1-[4-(5-carbamoylindol-3-yl)butyl]-4(2,3-dihydrobenzofuran-5-yl)piperidine; 
(d) 1-[4-(5-methoxyindol-3-yl)butyl]-4-(2,3-dihydrobenzofuran-5-yl)piperazine; 
(e) 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-ethoxycarbonylbenzofuran-5-yl)piperazine;  

 
(f) 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine; 
(g) 1-[4-(5-methoxyindol-3-yl)butyl]-4-(chroman-6-yl)piperazine; 
(h) 1-[4-(5-hydroxyindol-3-yl)butyl]-4-(chroman-6-yl)piperazine. 
Process for the preparation of piperazine and 
piperidine derivatives of the formula I according to 

Claim 1, and their salts, characterised in that a 
compound of the formula II 


Ind-Q-X
1
 
wherein 


X
1
is X or NH
2
, 
X
is Cl, Br, I, OH or an OH group functionally modified 
to form a reactive group, and 
 
Ind and Q are as defined,
 
is reacted with a compound of the formula III 


X
2
-(CH
2
)
2
-ZR
1
-(CH
2
)
2
-X
3
 
wherein 


X
2
 and X
3
can be identical or different and are each X if 
X
1
 = NH
2
 or are together NH in other cases, and 
Z and R
1
are as defined, 
 
or in that to prepare a compound of the formula I, in 

which Z is N, a compound of the formula IV 

Ind-Q-N(CH
2
-CH
2
-X)
2
 
wherein
 
X, Q and Ind are as defined, is reacted with a compound 

of the formula V 

R
1
-NH
2
 
wherein
 
R
1
 is as defined,
 
or in that a compound which has formula I except that one 

or more hydrogen atoms have been replaced by one or more 
reducible groups and/or one or more additional C-C and/or 

C-N bonds is treated with a reducing agent,
 
or in that a compound which has formula I except that one 

or more hydrogen atoms have been replaced by one or more 
solvolysable groups is treated with a solvolysing agent,  

 
and/or in that an OA group is optionally cleaved to form 

an OH group, and/or an Ind group or an R
1
 group is converted 
into another Ind and/or R
1
 group, and/or in that 
a resulting base or acid of the formula I is converted 

into one of its salts by treatment with an acid or base. 
Process for the manufacture of pharmaceutical 
preparations, characterized in that a compound of the 

formula I according to Claim 1 and/or one of its 
physiologically acceptable salts are converted into a 

suitable dosage form together with at least one solid, 
liquid or semiliquid excipient or adjunct. 
Pharmaceutical preparation, characterized in that 
it contains at least one compound of general formula I 

according to Claim 1 and/or one of its physiologically 
acceptable salts. 
Use of compounds of the formula I according to 
Claim 1, or their physiologically acceptable salts, for 

the manufacture of a drug. 
</CLAIMS>
</TEXT>
</DOC>
